74702-93-5

Basic information

• Product Name: 1-(3-Bromophenyl)-1-methylethylamine
• Synonyms: 1-(3-BROMOPHENYL)-1-METHYLETHYLAMINE;1-(1-Amino-1-methylethyl)-3-bromobenzene;2-(3-broMophenyl)propan-2-aMine;3-Bromo-alpha,alpha-dimethylbenzenemethanamine
• CAS NO: 74702-93-5
• Molecular Formula: C₉H₁₂BrN
• Molecular Weight: 214.1
• Mol File: 74702-93-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 246 °C
• Flash Point: 102 °C
• Appearance: /
• Density: 1.342
• Refractive Index: 1.555
• PKA: 9.05±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Bromophenyl)-1-methylethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Bromophenyl)-1-methylethylamine(74702-93-5)
• EPA Substance Registry System: 1-(3-Bromophenyl)-1-methylethylamine(74702-93-5)

Safety Data

• Hazardous Substances Data: 74702-93-5(Hazardous Substances Data)

Usage

General Description

1-(3-Bromophenyl)-1-methylethylamine, also known as meta-bromoamphetamine, is a chemical compound with the molecular formula C9H12BrN. It is a substituted phenethylamine derivative that acts as a serotonin, dopamine, and norepinephrine releasing agent. 1-(3-Bromophenyl)-1-methylethylamine has been used as a research chemical and is not approved for human consumption. It is known to have psychoactive effects and may have potential applications in the field of pharmacology and neuroscience research. However, due to its potential for abuse and lack of safety data, it is not suitable for human use and is classified as a controlled substance in many jurisdictions.

InChI:InChI=1/C9H12BrN/c1-9(2,11)7-4-3-5-8(10)6-7/h3-6H,11H2,1-2H3

Upstream product

• 861840-21-3 N-(2-(3-bromophenyl)propan-2-yl)-2-chloroacetamide 
• 6952-59-6 3-cyanobromobenzene 
• 917-54-4 methyllithium 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 30951-66-7 2-(3-bromophenyl)-2-propanol 

Downstream Products

• 676135-18-5 2-(3-bromophenyl)propan-2-amine hydrochloride 
• 1190380-47-2 4-(2-(3-bromophenyl)propan-2-yl)morpholine 
• 214964-87-1 tert-butyl [2-(3-bromophenyl)propan-2-yl]carbamate 
• 1255924-90-3 2-(2-(3-bromophenyl)propan-2-ylamino)-1-(3,4-dichlorophenyl)ethanone 
• 1255924-92-5 2-(2-(3-bromophenyl)propan-2-ylamino)-1-(3,4-dichlorophenyl)ethanol 
• 1190374-98-1 3-(1-methyl-1-morpholin-4-yl-ethyl)-phenylamine 
• 1190380-48-3 benzhydrylidene-[3-(1-methyl-1-morpholin-4-yl-ethyl)-phenyl]-amine 
• 1255924-93-6 7-bromo-4-(3,4-dichlorophenyl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-09-4 4-(3,4-dichlorophenyl)-1,1-dimethyl-7-(pyridazin-3-yl)-1,2,3,4-tetrahydroisoquinoline 
• 1255924-95-8 4-(3,4-dichlorophenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255923-87-5 4-(3,4-dichlorophenyl)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-20-9 4-(3,4-dichlorophenyl)-7-(6-aminopyridazin-3-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 1255924-12-9 4-(3,4-dichlorophenyl)-7-(6-(trifluoromethyl)pyridazin-3-yl)-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Synthesis of 4H-1,3-Benzoxazines via Metal- and Oxidizing Reagent-Free Aromatic C-H Oxygenation

An unprecedented electrochemical aromatic C-H oxygenation reaction for the synthesis of 4H-1,3-benzoxazines from easily available N-benzylamides is reported. These oxidative cyclization reactions proceed in a transition metal- and oxidizing reagent-free fashion and produce H2 as only theoretical byproduct. Adapting the C-H oxygenation reaction in an electrochemical microreactor has been demonstrated.

Pyrrolopyrimidines and Pyrrolopyridines

Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES

Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.